Последние добавленные видео:
Speaker:-Hope-Rugo
-
5 лет назад
186 5 лет назад 3:23Should chemotherapy be used in post-menopausal patients with low genomic risk HR+ breast cancer?
-
5 лет назад
613 5 лет назад 3:32Sequencing novel HER2-targeted therapies in metastatic breast cancer
-
6 лет назад
1180 6 лет назад 5:14Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts
-
14 лет назад
603 14 лет назад 7:13Hope Rugo, MD: Chemotherapy Agents and Breast Cancer Treatment
-
3 года назад
2804 3 года назад 5:28CAPItello-291: capivasertib +fulvestrant for AI-resistant HR+/HER2- advanced breast cancer
-
3 года назад
969 3 года назад 5:07TROPiCS-02: sacituzumab govetican improves PFS versus physicians choice for HR+/HER2- mBC
-
3 года назад
994 3 года назад 3:07BYLieve Study Cohort A: alpelisib + ET in PIK3CA-mutant, HR+, HER2-, advanced breast cancer
-
2 года назад
1358 2 года назад 3:24What to look forward to in breast cancer at ASCO 2023
-
1 год назад
101 1 год назад 2:04Utilizing TILs to stratify treatment strategies in breast cancer
-
3 года назад
4090 3 года назад 4:03MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC
-
5 лет назад
1083 5 лет назад 5:06Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer
-
1 год назад
1047 1 год назад 2:41Evaluating the role of chemotherapy in triple-negative breast cancer
-
3 года назад
8592 3 года назад 4:12Optimizing treatment in patients with early-stage HER2-positive breast cancer
-
2 года назад
579 2 года назад 14:31P-REALITY-X: Real-world, overall survival with palbociclib + aromatase inhibitor in HR+/HER2- MBC
-
1 год назад
161 1 год назад 2:38Novel ADC and checkpoint inhibitor combinations in breast cancer
-
6 лет назад
179 6 лет назад 4:46Performance of PD-L1 IHC assays in IMpassion130: a post-hoc analysis
-
2 года назад
263 2 года назад 4:01KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEs